Researchers Identify Gene Involved In Brain, Breast, And Prostate Cancer

March 28, 1997

NEW YORK, NY- Researchers at Columbia-Presbyterian Medical Center, in collaboration with Cold Spring Harbor Laboratory, have identified a new tumor suppressor gene, known as P-TEN, involved in a large percentage of brain, breast, and prostate cancers. The newly discovered tumor suppressor gene is one of more than a dozen known to be involved in a large variety of cancers. The discovery could lead to better tests for early detection and more effective treatments.

The finding is reported in the March 28 issue of the journal, Science. Senior author Ramon Parsons, M.D., Ph.D., assistant professor of pathology and medicine in the Herbert Irving Comprehensive Cancer Center and the departments of pathology and medicine at Columbia-Presbyterian Medical Center, made the finding together with Michael Wigler, Ph.D., of Cold Spring Harbor Laboratory.

"Although initially mutated in breast cancer, we found mutations of P-TEN in brain and prostate cancer and expect to find mutations in other cancers as well," says Dr. Parsons. Unlike mutations of genes such as hMSH2 and BRCA1, which are found in hereditary predispositions to cancer, most P-TEN mutations are found in the more common sporadic cancers. More than 80 percent of all cases of cancer are sporadic.

"Discoveries such as this are rapidly filling in the missing pieces of the cancer puzzle. This discovery represents one of the first genes to be implicated in aggressive and generally fatal brain tumors, a type of cancer in which we desperately need clues that the P-TEN gene may offer," said Richard Klausner, M.D., director of the National Cancer Institute.

There is some evidence to suggest that loss of P-TEN affects the way a benign tumor becomes malignant. "We identified 20 mutations of P-TEN in advanced brain, breast, and prostate cancers," says Dr. Parsons. "Based on our finding, it may someday be possible to test people for mutations of P-TEN, which would give an early warning of cancer danger. P-TEN may also allow us to identify drugs to better treat cancer overall." Although this discovery shows great promise, Dr. Parsons cautions that it is not likely to have an impact on patient care for many years.

P-TEN is located on chromosome 10. The role of this chromosome in the development of various sporadic cancers has been investigated for nearly a decade. For instance, scientists believe that the mutation that causes Cowden's syndrome, a genetic condition that often leads to breast cancer and other tumors, is located on chromosome 10.

P-TEN received its name from its similarity to phosphatases and to tensin, part of a complex of proteins that sits below the cell surface which may be involved in the spread of tumors. The similarity between P-TEN and protein phosphatases, which remove phosphates from proteins, is significant because many oncogenes--genes that activate tumors--are part of a class called tyrosine kinases, which add phosphates to proteins. "This will add a great deal of understanding to the picture of the genetic disarray that takes place when a cell becomes cancerous," says co-author Dr. Wigler.

Representational difference analysis (RDA), an advanced genetic technology developed by Dr. Wigler and Dr. Nikolai Lisitsyn then at Cold Spring Harbor Laboratory, played a key role in the identification of this gene. RDA is a procedure that analyzes the difference between two complex sets of genomes. A genome is the entire DNA sequence of an organism. By comparing DNA from diseased and normal cells from a person, the method can identify DNA sequences that differ between diseased and normal cells from the same person. RDA enriches DNA sequences for unique DNA regions of one of the genomes by removing shared sequences. In this case, RDA was used to find unique sequences present in normal tissue but missing in breast cancer.

Clifford Yen of the Wigler lab used RDA to obtain the first probe for the P-TEN gene. Steven Wang of the Parsons lab and Yen together mapped the probe to chromosome 10. Jing Li and Shikha Bose of the Parsons lab characterized the minimal deletion of chromosome 10 containing the P-TEN gene and along with Danny Liaw and Katrina Podsypanina identified the P-TEN gene and characterized its mutations. Drs. Beppino Giovanella (Stehlin Foundation); Sandra Bigner (Duke University); and Ben Tycko (Columbia University) provided critical tumor material for this project.

The study was funded by the departments of medicine and pathology at Columbia University College of Physicians & Surgeons, Cold Spring Harbor Laboratory, the James S. McDonnell Foundation, the National Cancer Institute, the Department of the Army, Amplicon Corporation, and "1 in 9," a breast cancer advocacy group.

REPORTERS PLEASE NOTE:
A PRESS CONFERENCE WILL BE HELD THURSDAY, MARCH 27, AT NOON IN THE COLUMBIA-PRESBYTERIAN EASTSIDE CONFERENCE ROOM 470 LOCATED AT 16 EAST 60TH STREET.
-end-


Columbia University Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.